2026-11-10 10:23:53 UTC#607002newconfirmedanalysis
AbbVie (ABBV) stock news
AbbVie (ABBV) stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-11-08 17:45:00 UTC#596290duplicateconfirmedpress release
Allergan Aesthetics reports positive patient satisfaction data for facial treatments in GLP-1 medication users
2026-11-07 15:00:00 UTC#594659newconfirmednews
Organon reports 1.3% HADLIMA switchback rate in VA study, citing $8,100 per-patient annual pharmacy cost savings
tradingviewimportance 0.40trust 0.70Organon & Co. +0.40AbbVie Inc. -0.20United States Department of Veterans Affairs +0.20
2026-11-04 18:22:32 UTC#573947duplicateconfirmednews
AbbVie and Nxera Pharma finalize licensing agreement for bowel disease therapy worth up to $1.5 billion
2026-11-04 08:41:00 UTC#569756newconfirmedpress release
Nxera Pharma licenses IBD drug candidate NXE0033744 to AbbVie in deal worth up to $1.47 billion
yahooimportance 0.60trust 0.90Nxera Pharma Co., Ltd. +0.80AbbVie Inc. +0.40NXE0033744 +0.60+1 entities
2026-11-04 00:08:00 UTC#567168newconfirmednews
AbbVie to invest over £120 million to expand R&D facility in Oxford, UK
2026-11-03 19:41:00 UTC#565556newreportednews
Medicaid work requirements threaten $42B in annual drug sales, Health Management Associates report says
dow_jonesimportance 0.60trust 0.70Health Management Associates -0.40Gilead Sciences, Inc. -0.30Novo Nordisk A/S -0.30+2 entities
2026-11-03 18:51:01 UTC#565331newconfirmeddata release
AbbVie reports Q3 2026 revenue of $17.4B and diluted EPS of $2.37
2026-11-03 13:00:00 UTC#562875newconfirmedpress release
Allergan Aesthetics to present new research on post-weight loss aesthetic care at ASDS 2026
yahooimportance 0.30trust 0.90Allergan Aesthetics +0.30AbbVie Inc. +0.20American Society for Dermatologic Surgery +0.10+2 entities
2026-11-02 21:20:06 UTC#558298newconfirmednews
UBS maintains AbbVie at Neutral, raises price target to $295 from $275
2026-11-02 20:02:54 UTC#557800newconfirmednews
Leerink Partners maintains AbbVie at Outperform, raises price target to $342 from $309
2026-11-02 17:54:00 UTC#557457newconfirmednews
AbbVie and Teva face trial in cholesterol drug pay-for-delay antitrust lawsuit
bloomberg law newsimportance 0.40trust 0.90AbbVie Inc. -0.30Teva Pharmaceutical Industries Ltd. -0.30
2026-11-02 17:36:00 UTC#557096duplicateconfirmednews
Morgan Stanley raises AbbVie price target to $346 from $310
2026-11-02 17:25:08 UTC#557045newconfirmednews
Morgan Stanley maintains AbbVie at Overweight, raises price target to $346 from $310
2026-11-02 15:06:54 UTC#556165newconfirmednews
AbbVie reports positive Phase 3 TEMPLE trial results for Qulipta in migraine prevention
2026-11-02 14:13:43 UTC#555683newconfirmednews
Guggenheim maintains AbbVie at Buy, raises price target to $322 from $288
2026-11-02 14:05:24 UTC#555594newconfirmedpress release
Brise Pharmaceuticals signs global migraine therapy licensing deal with AbbVie worth up to $757 million
2026-11-02 13:23:53 UTC#555303newconfirmednews
RBC Capital maintains AbbVie at Outperform, raises price target to $330 from $280
2026-10-30 22:20:00 UTC#548674newconfirmednews
AbbVie Inc. average analyst price target raised to $291, consensus Buy rating maintained
2026-10-30 21:37:00 UTC#548560newconfirmednews